patientsGlioblastoma is the most aggressive form of brain cancer, unfortunately with only limited therapeutic options and very poor prognosis. Thus, there is an urgent medical need for new therapeutic approaches.  Previous experience in first vaccination trials has indicated encouraging immune responses to vaccinations in these patients.
Within the GAPVAC project, patients presenting with fully resectable, suspected glioblastoma are treated by a vaccine, especially designed and manufactured according to characteristics of his/her individual disease. First, the tumor surgically resected is analyzed. During this time, patients start their standard therapy (chemoradiotherapy). As soon as the personalized vaccine is available, patients are repeatedly vaccinated on top of the standard therapy.

Several European hospitals take care of patients recruited to the clinical trial and treat patients with standard therapy and the novel APVAC approach.